Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis

European Respiratory Journal

Volumn 38, Issue 1, 2011, Pages 59-69

  Wilschanski, M ^a   Miller, L L ^e   Shoseyov, D ^a   Blau, H ^b   Rivlin, J ^c   Aviram, M ^d   Cohen, M ^a   Armoni, S ^a   Yaakov, Y ^a   Pugatch, T ^a   Cohen Cymberknoh, M ^a   Miller, N L ^e   Reha, A ^e   Northcutt, V J ^e   Hirawat, S ^e   Donnelly, K ^e   Elfring, G L ^e   Ajayi, T ^e   Kerem, E ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b SCHNEIDER CHILDREN'S HOSPITAL   (United States)

^c CARMEL MEDICAL CENTER   (Israel)

^d BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^e PTC THERAPEUTICS   (United States)

Author keywords

Adult; Cough; Cystic fibrosis transmembrane conductance regulator; Investigational drug; Nasal potential difference; Nonsense mutation

Indexed keywords

ATALUREN; CHLORIDE;

ADRENAL CORTEX INSUFFICIENCY; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; CFTR GENE; CHLORIDE TRANSPORT; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; CYSTIC FIBROSIS; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG ERUPTION; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; DYSURIA; EVENING DOSAGE; FEMALE; GENE; GENE FUNCTION; HUMAN; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERPOLARIZATION; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPONATREMIA; LONG TERM CARE; LUNG FUNCTION; MALE; MORNING DOSAGE; MYCOSIS; NONSENSE MUTATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; RESPIRATORY TRACT INFECTION; RHINITIS; RHINOPHARYNGITIS; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; UNSPECIFIED SIDE EFFECT; UREA NITROGEN BLOOD LEVEL; URINARY TRACT INFECTION; VIRUS INFECTION;

ADULT; CODON, NONSENSE; CODON, TERMINATOR; COUGH; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FEMALE; HUMANS; MALE; MIDDLE AGED; OXADIAZOLES; PROGNOSIS; RIBOSOMES; TREATMENT OUTCOME;

EID: 79960187095     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00120910     Document Type: Article

References (49)

1. Hanrahan JW, Wioland MA. Revisiting cystic fibrosis transmembrane conductance regulator structure and function. Proc Am Thorac Soc 2004; 1: 17-21.
2. O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet 2009; 373: 1891-1904.
3. Corey M, Edwards L, Levison H, et al. Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. J Pediatr 1997; 131: 809-814. (Pubitemid 28027602)
4. Harrison F. Microbial ecology of the cystic fibrosis lung. Microbiology 2007; 153: 917-923. (Pubitemid 46605791)
5. Sawicki GS, Sellers DE, Robinson WM. Self-reported physical and psychological symptom burden in adults with cystic fibrosis. J Pain Symptom Manage 2008; 35: 372-380.
6. VanDevanter DR, Rasouliyan L, Murphy TM, et al. Trends in the clinical characteristics of the U.S. cystic fibrosis patient population from 1995 to 2005. Pediatr Pulmonol 2008; 43: 739-744.
7. Kerem E, Wilschanski M, Ajayi T, et al. Objective cough assessment over a 24-hour period in patients with cystic fibrosis. Pediatr Pulmonol 2009; 44: Suppl. 32, 342.
8. Kerem E, Reisman J, Corey M, et al. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992; 326: 1187-1191.
9. Schluchter MD, Konstan MW, Davis PB. Jointly modelling the relationship between survival and pulmonary function in cystic fibrosis patients. Stat Med 2002; 21: 1271-1287. (Pubitemid 34467234)
10. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994; 331: 637-642. (Pubitemid 24276863)
11. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999; 340: 23-30. (Pubitemid 29024680)
12. Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006; 354: 229-240. (Pubitemid 43113028)
13. Bobadilla JL, Macek M Jr, Fine JP, et al. Cystic fibrosis: a worldwide analysis of CFTR mutations - correlation with incidence data and application to screening. Hum Mutat 2002; 19: 575-606. (Pubitemid 34556480)
14. Kerem B, Chiba-Falek O, Kerem E. Cystic fibrosis in Jews: frequency and mutation distribution. Genet Test 1997; 1: 35-39. (Pubitemid 127526935)
15. Shoshani T, Augarten A, Gazit E, et al. Association of a nonsense mutation (W1282X), the most common mutation in the Ashkenazi Jewish cystic fibrosis patients in Israel, with presentation of severe disease. Am J Hum Genet 1992; 50: 222-228.
16. de Gracia J,Mata F,Alvarez A, et al. Genotype-phenotype correlation for pulmonary function in cystic fibrosis. Thorax 2005; 60: 558-563.
17. McKone EF, Goss CH, Aitken ML. CFTR genotype as a predictor of prognosis in cystic fibrosis. Chest 2006; 130: 1441-1447. (Pubitemid 44786738)
18. Welch EM, Barton ER, Zhuo J, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007; 447: 87-91. (Pubitemid 46685839)
19. Du M, Liu X, Welch EM, et al. PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Proc Natl Acad Sci USA 2008; 105: 2064-2069. (Pubitemid 351439465)
20. Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008; 372: 719-727.
21. Wilschanski M, Armoni S, Yaakov Y, et al. PTC124 treatment over 3 months improves pharmacodynamic and clinical parameters in patients with nonsense-mutation-mediated CF. J Cystic Fibrosis 2008; 7: Suppl. 2, S22.
22. Kerem E, Yaakov Y, Armoni S, et al. PTC124™ induces time-dependent improvements in chloride conductance and clinical parameters in patients with nonsense mutation cystic fibrosis. Pediatr Pulmonol 2008; 43: Suppl. 31, 294.
23. Wilschanski M, Famini H, Strauss-Liviatan N, et al. Nasal potential difference measurements in patients with atypical cystic fibrosis. Eur Respir J 2001; 17: 1208-1215. (Pubitemid 32717480)
24. Standaert TA, Boitano L, Emerson J, et al. Standardized procedure for measurement of nasal potential difference: an outcome measure in multicenter cystic fibrosis clinical trials. Pediatr Pulmonol 2004; 37: 385-392. (Pubitemid 38620059)
25. Hirawat S, Welch EM, Elfring GL, et al. Safety, tolerability, and pharmacokinetics of PTC124, a non-aminoglycoside, nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol 2007; 47: 430-414.
26. Schüler D, Sermet-Gaudelus I, Wilschanski M, et al. Basic protocol for transepithelial nasal potential difference measurements. J Cystic Fibrosis 2004; 3: 151-155. (Pubitemid 40045589)
27. Miller MR, Crapo R, Hankinson J, et al. General considerations for lung function testing. Eur Respir J 2005; 26: 153-161. (Pubitemid 40945944)
28. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319-338. (Pubitemid 41079078)
29. Coyle MA, Keenan DB, Henderson LS, et al. Evaluation of an ambulatory system for the quantification of cough frequency in patients with chronic obstructive pulmonary disease. Cough 2005; 1: 3.
30. Knowles MR, Paradiso AM, Boucher AM. In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. Hum Gene Ther 1995; 6: 445.
31. Clancy JP, Bebok Z, Ruiz F, et al. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med 2001; 163: 1683-1692. (Pubitemid 32578776)
32. Sermet-Gaudelus I, Dechaux M, Vallee B, et al. Chloride transport in nasal ciliated cells of cystic fibrosis heterozygotes. Am J Respir Crit Care Med 2005; 171: 1026-1031. (Pubitemid 40616953)
33. Knudson RJ, Lebowitz MD, Holberg CJ, et al. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983; 127: 725-734. (Pubitemid 13101554)
34. Highsmith WE, Burch LH, Zhou Z, et al. A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. N Engl J Med 1994; 331: 974-980. (Pubitemid 24304583)
35. Espiritu JD, Kleinhenz ME. Paradoxical embolization in an adult patient with cystic fibrosis. Mayo Clin Proc 2000; 75: 1100-1102.
36. Sritippayawan S, MacLaughlin EF, Woo MS. Acute neurological deficits in a young adult with cystic fibrosis. Pediatr Pulmonol 2003; 35: 147-151. (Pubitemid 36177111)
37. Rao DS, Infeld MD, Stern RC, et al. Cough-induced hemiplegic migraine with impaired consciousness in cystic fibrosis. Pediatr Pulmonol 2006; 41: 171-176. (Pubitemid 43165447)
38. Jones AM, Helm JM. Emerging treatments in cystic fibrosis. Drugs 2009; 69: 1903-1910.
39. Ginsburg GS, Willard HF. Genomic and personalized medicine: foundations and applications. Transl Res 2009; 154: 277-287.
40. Swiatecka-Urban A, Brown A, Moreau-Marquis S, et al. The short apical membrane half-life of rescued ΔF508-cystic fibrosis transmembrane conductance regulator (CFTR) results from accelerated endocytosis of ΔF508-CFTR in polarized human airway epithelial cells. J Biol Chem 2005; 280: 36762-36772. (Pubitemid 41587756)
41. Zhang L, Button B, Gabriel SE, et al. CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium. PLoS Biol 2009; 7: e1000155.
42. Sermet-Gaudelus I, De Boeck K, Casimir GJ, et al. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am J Respir Crit Care Med 2010; 182: 1262-1272.
43. Johnson LG, Olsen JC, Sarkadi B, et al. Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nat Genet 1992; 2: 21-25.
44. Kuzniar TJ, Morgenthaler TI, Afessa B, et al. Chronic cough from the patient's perspective. Mayo Clin Proc 2007; 82: 56-60. (Pubitemid 46036321)
45. Kelsall A, Decalmer S, Webster D, et al. How to quantify coughing: correlations with quality of life in chronic cough. Eur Respir J 2008; 32: 175-179.
46. Irwin RS. Assessing cough severity and efficacy of therapy in clinical research: ACCP evidence-based clinical practice guidelines. Chest 2006; 129: Suppl. 1, 232S-237S.
47. Morice AH, Fontana GA, Belvisi MG, et al. ERS guidelines on the assessment of cough. Eur Respir J 2007; 29: 1256-1276.
48. Decalmer SC, Webster D, Kelsall AA, et al. Chronic cough: how do cough reflex sensitivity and subjective assessments correlate with objective cough counts during ambulatory monitoring? Thorax 2007; 62: 329-334.
49. Riebling P. PTC Therapeutics, Inc. Study of Ataluren (PTC124) in Cystic Fibrosis. http://clinicaltrials.gov/ct2/show/NCT00803205 Date last updated: December 8, 2010.